Buprenorphine and methadone in the treatment of opioid dependence: Methods and design of the COBRA study

International Journal of Methods in Psychiatric Research

Volumn 14, Issue 1, 2005, Pages 14-28

  Wittchen, Hans Ulrich ^a   Apelt, Sabine M ^a   Bühringer, Gerhard ^b   Gastpar, Markus ^c   Backmund, Markus ^d   Gölz, Jörg ^e   Kraus, Michael R ^f   Tretter, Felix ^g   Klotsche, Jens ^a   Siegert, Jens ^a   Pittrow, David ^h   Soyka, Michael ⁱ  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b IFT INSTITUT FÜR THERAPIEFORSCHUNG   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d Klinikum Schwabing   (Germany)

^e Praxiszentrum Kaiserdamm   (Germany)

^f UNIVERSITY OF WÜRZBURG   (Germany)

^g Bezirkskrankenhaus München Haar   (Germany)

^h 3P Consulting   (Germany)

ⁱ UNIVERSITY OF MUNICH   (Germany)

Author keywords

Buprenorphine; Course; Epidemiology; Hepatitis C; Methadone; Opioid dependence; Outcome

Indexed keywords

BUPRENORPHINE; METHADONE;

ARTICLE; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG SURVEILLANCE PROGRAM; FOLLOW UP; HEPATITIS C; HUMAN; LONGITUDINAL STUDY; OPIATE ADDICTION; PATIENT COMPLIANCE; PHYSICIAN; REGISTER; SAMPLING; TREATMENT OUTCOME;

EID: 18144385419     PISSN: 10498931     EISSN: None     Source Type: Journal    
DOI: 10.1002/mpr.14     Document Type: Article

References (38)

1. Brooks R, Rabin R, de Charro F (eds). The Measurement and Valuation of Health Status using EQ-5D: A European Perspective. Amsterdam: Kluwer Academic Publishers, 2003.
2. Carey KB, Purnine DM, Maisto SA, Carey MP. Assessing readiness to change substance abuse: A critical review of instruments. Clinical Psychology: Science and Practice 1999; 6: 245-366
3. Christl B, Gerlach R. Fragebogen für substituierende Ärzte/Ärztinnen (Methadone-Buprenorphine staff questionnaire. Caplehorn JRM 2002). Dresden: Technical University Dresden, Institute of Clinical Psychology and Psychotherapy, 2003.
4. Farell M, Howes S, Verster A, Davoli M, Solberg U, Greenwood G, Robertson K (eds). Reviewing Current Practice in Drug-substitution Treatment in the European Union. Insights 3, EMCDDA Series. Luxembourg: Office for Official Publications of the European Communities, 2000.
5. Gerra G, Borella F, Zaimovic A, Moi G, Bussandri M, Bubici C, Bertacca S. Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend 2004; 75(1): 37-45.
6. Gossop M. The development of a short opiate withdrawal scale (SOWS). Addict Behav 1990; 15(5): 487-90.
7. Groß A, Soyka M. Buprenorphin - ein neuer Ansatz in der Pharmakotherapie opiatabhängiger Patienten (Buprenorphine - a new approach to pharmacotherapy of opiate-addicted patients). Suchtmedizin 1999; 1(1): 5-14.
8. Gsellhofer B, Küfner H, Vogt M, Weiler D. European Addiction Severity Index - EuropASI. Manual für Training und Durchführung [Manual for training and execution]. Stuttgart: Schneider Verlag, 1999.
9. Guy W. Clinical global impressions. In National Institute of Mental Health (ed.) ECDEU Assessment for Psychopharmacology. 1 edn. Rockville: National Institute of Mental Health, 1976, pp. 221-7.
10. Johnson R-E, Jaffe J-H, Fudala P-J. A controlled trial of buprenorphine treatment for opioid dependence. J Am Med Assoc 1992; 267(20): 2750-5.
11. Johnson W-A, Sterk C-E. Late-onset crack users: an emergent HIV risk group. J Acquir Immune Defic Syndr 2003; 33 Suppl 2: 229-32.
12. Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet 2003; 361(9358): 662-8.
13. Kagerer S, Hock B, Wiese B, Lehnert R, Soyka M. Aufmerksamkeit, Konzentration und Gedächtnisleistung bei Opiatabhängigen unter Methadon und unter Buprenorphin (Attention, concentration and memory performance of opioid-dependent patients under methadone and under buprenorphine). Suchtmed 2004; 6(1): 93-4.
14. Kreek MJ. Biological correlates of methadone maintenance pharmocotherapy. Ann Med Interne (Paris) 1994; 145 Suppl 3: 9-14.
15. Kuefner H, Vogt M, Indlekofer W. Test-Manual PREDI 2.0. München: Bayerische Akademie für Suchtfragen in Forschung und Praxis BAS eV, 2001.
16. Kuefner H, Hackmann K, Schnabel A, Soyka M. Optimierung der substitutionsgestützten Therapie Drogenabhängiger (OSTD): Entzugssymptome und Suchtverlangen in der ersten Einstellungswoche (Optimising substitution therapy for drug-dependent patients (OSTD): withdrawal symptoms and craving in the first treatment week). Suchtmed 2004; 6(1): 95-7.
17. Law FD, Nutt DJ. Maintenance buprenorphine for opioid users. Lancet 2003; 361(9358): 634-5.
18. Layson-Wolf C, Goode JV, Small RE. Clinical use of methadone. J Pain Palliat Care Pharmacother 2002; 16(1): 29-59.
19. Ling W, Charuvastra C, Kaim SC, Klett CJ. Methadyl acetate and methadone as maintenance treatments for heroin addicts. a veterans administration cooperative study. Arch Gen Psychiatry 1976; 33(6): 709-20.
20. Ling W, Wesson D-R. Clinical efficacy of buprenorphine: comparisons to methadone and placebo. Drug Alcohol Depend 2003; 70(2) Suppl: 49-57.
21. McLellan AG, Arndt IO, Metzger DS, Woody GE, O'Brien CP. The effects of psychosocial services in substance abuse treatment. J Am Med Assoc 1993; 269: 1953-9.
22. Mattick RP, Ali R, White JM, O'Brien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction 2003; 98(4): 441-52.
23. Mattick RP, Breen C, Kimber J, Davioli M. Methadone maintenance therapy versus no opioid treplacement therapy for opioid dependence (Cochrane Review). The Cochrane Library, 4. Chichester: Wiley, 2004.
24. Mintzer M-Z, Stitzer M-L. Cognitive impairment in methadone maintenance patients. Drug Alcohol Depend 2002; 67(1): 41-51.
25. Petitjean S, Stohler R, Deglon JJ, Livoti S, Waldvogel D, Uehlinger C, Ladewig D. Double-blind randomized trial of buprenorphine and methadone in opioid dependence. Drug Alcohol Depend 2001; 62(1): 97-104.
26. Poser S, Poser W. Medikamente - Missbrauch und Abhängigkeit: Entstehung. Verlauf. Behandlung (Pharmaceuticals and dependence: onset, course, treatment). Stuttgart: Thieme, 1996.
27. San L, Cami J, Peri JM, Mata R, Porta M. Efficacy of clonidine, guanfacine and methadone in the rapid detoxification of heroin addicts: a controlled clinical trial. Br J Addict 1990; 85(1): 141-7.
28. Soyka M, Banzer K, Buchberger R, Völkl M, Naber D. Methadon-Substitution Opiatabhängiger (Methadone substitution in opioid dependence). Nervenheilkunde 1997; 16: 347-52.
29. Soyka M, Fischer G, Ladewig D, Blanke J, Nowak M, Poehlke T, Penning R, Liess H, Schütz C, Küfner H. Empfehlungen zur Anwendung von Buprenorphin (SUBUTEX) in der Substitutionsbehandlung opiatabhängiger Patienten in der Schweiz, Österreich und Deutschland (Konsensustexte) (Recommendations for buprenorphine (SUBUTEX) substitution therapy for opioid-dependent patients in Switzerland, Austria and Germany (consensus reports)). Suchtmed 2000; 2(1): 43-53.
30. Sutherland G, Edwards G, Taylor C, Phillips G, Gossop M, Brady R. The measurement of opiate dependence. Br J Addict 1986; 81(4): 485-94.
31. Vollmer H-C, Krauth J. Therapie der Drogenabhängigkeit. In F Tretter, A Müller (eds) Psychologische Therapie der Sucht (Psychological Therapy of Addiction). Hogrefe. Göttingen, 2001, pp. 395-438.
32. Walsh SL, Gilson SL, Jasinski DR, Stapleton JM, Phillips RL, Dannals RF, Schmidt J, Preston KL, Grayson R, Bigelow GE, Sullivan JT, Contoreggi C, London ED. Buprenorphine reduces cerebral glucose metabolism in polydrug abusers. Neuropsychopharmacology 1994; 10: 157-70.
33. Waal H, Haga E. Maintenance Treatment of Heroin Addiction: Evidence at the Crossroads. Oslo: Cappelen Akademisk Forlag, 2003.
34. Wittchen H-U. Reliability and validity studies of the WHO-Composite International Diagnostic Interview (CIDI): a critical review. Journal of Psychiatric Research 1994a; 28(1): 57-84.
35. Wittchen H-U, Pfister, H. DIA-X-Interviews: Manual für Screening-Verfahren und Interview (Manual for screening procedure and interview); Ergänzungsheft (DIA-X-12 Monate) (Supplement (DIA-X 12 months)). Frankfurt: Swets and Zeitlinger, 1997.
36. Wittchen H-U, Lachner G, Wunderlich U, Pfister H. Test-retest reliability of the computerized DSM-IV Version of the Munich-Composite International Diagnostic Interview (M-CIDI). Social Psychiatry and Psychiatric Epidemiology 1998; 33(11): 568-78.
37. Wittchen H-U, Höfler M, Meister W. Prevalence and recognition of depressive syndromes in German primary care settings: poorly recognized and treated? International Clinical Psychopharmacology 2001; 16(3): 121-35.
38. Wittchen H-U, Apelt SM, Christl B, Hagenau K, Groß A, Klotsche J, Soyka M. Die Versorgungspraxis der Substitutionstherapie Opiatabhängiger (COBRA) [The practice of supply in the substitution therapy for opiate addicts (COBRA)]. Suchtmedizin in Forschung und Praxis 2004; 6(1): 80-7.